耐受性树突状细胞对急性肾损伤的保护作用
缺血再灌注损伤是急性肾损伤的常见诱因,本研究评估了维生素D3/IL-10诱导的耐受性树突状细胞的表型和基因组特征,并在小鼠中测试其过继转移能否减轻肾损伤。结果显示这些细胞经全身输注可消除肾损伤而不改变浸润炎症细胞群,且在脂质体氯膦酸盐预处理小鼠中仍具保护作用,提示该过程由活细胞而非再加工细胞调控;共培养和空间转录组分析证实肾小管上皮细胞损伤减少。
要点
- 维生素D3/IL-10诱导的耐受性树突状细胞高表达PD-L1:CD86、IL-10升高、IL-12p70分泌受限并抑制转录组炎症特征。
- 全身输注耐受性树突状细胞可消除肾损伤,且不改变浸润炎症细胞群。
- 在脂质体氯膦酸盐预处理小鼠中仍具保护作用,提示由活细胞调控;共培养和空间转录组证实肾小管上皮细胞损伤减少。
核心结论
- 围手术期给予耐受性树突状细胞能够预防急性肾损伤,需进一步探索作为治疗选择。
研究设计与样本
- 评估骨髓来源同基因或异基因、经维生素D3/IL-10诱导的耐受性树突状细胞的表型和基因组特征,并在小鼠中测试过继转移对缺血再灌注损伤的保护作用。
主要发现
- 耐受性树突状细胞高PD-L1:CD86、IL-10升高、IL-12p70分泌受限并抑制转录组炎症特征。
- 全身输注这些细胞成功消除肾损伤而不改变浸润炎症细胞群。
- 在脂质体氯膦酸盐预处理小鼠中仍提供缺血再灌注损伤保护,提示过程由活细胞而非再加工细胞调控。
- 共培养实验和空间转录组分析证实肾小管上皮细胞损伤减少。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出需进一步探索作为治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ischemia reperfusion injury is a common precipitant of acute kidney injury that occurs following disrupted perfusion to the kidney. This includes blood loss and hemodynamic shock, as well as during retrieval for deceased donor kidney transplantation. Acute kidney injury is associated with adverse long-term clinical outcomes and requires effective interventions that can modify the disease process. Immunomodulatory cell therapies such as tolerogenic dendritic cells remain a promising tool, and here we tested the hypothesis that adoptively transferred tolerogenic dendritic cells can limit kidney injury. The phenotypic and genomic signatures of bone marrow-derived syngeneic or allogeneic, Vitamin-D3/IL-10-conditioned tolerogenic dendritic cells were assessed. These cells were characterized by high PD-L1:CD86, elevated IL-10, restricted IL-12p70 secretion and a suppressed transcriptomic inflammatory profile. When infused systemically, these cells successfully abrogated kidney injury without modifying infiltrating inflammatory cell populations. They also provided protection against ischemia reperfusion injury in mice pre-treated with liposomal clodronate, suggesting the process was regulated by live, rather than reprocessed cells. Co-culture experiments and spatial transcriptomic analysis confirmed reduced kidney tubular epithelial cell injury. Thus, our data provide strong evidence that peri-operatively administered tolerogenic dendritic cells have the ability to protect against acute kidney injury and warrants further exploration as a therapeutic option. This technology may provide a clinical advantage for bench-to-bedside translation to affect patient outcomes.
引用
- Li JSY, Robertson H, Trinh K, et al. Tolerogenic dendritic cells protect against acute kidney injury. Kidney Int. 2023. PMID: 37244471. doi:10.1016/j.kint.2023.05.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。